Back to search

Italy· 042017018

CINRYZE*2 flaconcini EV 500 U + 2 flaconcini solv 10 ml

A medicinal product containing proteina del plasma umano antiangioedema, registered in Italy by TAKEDA MANUFACTURING AUS. AG, on the national reimbursement list.

Reimbursed in Italy (AIFA class A)

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedCINRYZE*2 flaconcini EV 500 U + 2 fla…ATC—REGISTER NO.042017018PACKS LISTED1CHECKEDJune 4, 2026

The record

At a glance

Active substance
Proteina del plasma umano antiangioedema
Manufacturer
TAKEDA MANUFACTURING AUS. AG
Country
Italy (IT)
ATC code
—
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    042017018
    CINRYZE*2 flaconcini EV 500 U + 2 flaconcini solv 10 ml
    EUR 1980.48

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c3ab6376-30a9-433b-9a7b-1e9d45eabfab
GET /v1/drugs/c3ab6376-30a9-433b-9a7b-1e9d45eabfab?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 1980.48,
  "source": "aifa",
  "currency": "EUR",
  "strength": "PROTEINA DEL PLASMA UMANO ANTIANGIOEDEMA 500U 2 UNITA' USO PARENTERALE",
  "substance": "Proteina del plasma umano antiangioedema",
  "equivalence_group": "R0B",
  "transparency_flag": null
}

See everything about proteina del plasma umano antiangioedema.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.